SIRT7 and central nervous system cancer: The aforementioned results suggested the miR-148a-3p/SIRT7 axis drives glioma progression and modulates TMZ sensitivity, and targeting this axis may represent a promising therapeutic approach to overcome TMZ resistance in glioma.